Levodopa‐induced dyskinesias
Identifieur interne : 001027 ( Main/Exploration ); précédent : 001026; suivant : 001028Levodopa‐induced dyskinesias
Auteurs : Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-07-30.
English descriptors
- KwdEn :
Abstract
Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms also occur, making the evaluation and choice of treatment complicated. A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway. This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata. Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism. Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, α2 adrenergic, serotonergic (5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid CB1 receptors systems. The only currently available drug with an evidence‐based recommendation on efficacy for dyskinesia is amantadine. Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically. New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21475
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa‐induced dyskinesias</title><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Grandas, Francisco" sort="Grandas, Francisco" uniqKey="Grandas F" first="Francisco" last="Grandas">Francisco Grandas</name></author><author><name sortKey="Nomoto, Masahiro" sort="Nomoto, Masahiro" uniqKey="Nomoto M" first="Masahiro" last="Nomoto">Masahiro Nomoto</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CC3323805F38A8257F0A40F3113E504989102B49</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21475</idno><idno type="url">https://api.istex.fr/document/CC3323805F38A8257F0A40F3113E504989102B49/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000224</idno><idno type="wicri:Area/Main/Curation">000186</idno><idno type="wicri:Area/Main/Exploration">001027</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa‐induced dyskinesias</title><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences University of Rome “La Sapienza”, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Grandas, Francisco" sort="Grandas, Francisco" uniqKey="Grandas F" first="Francisco" last="Grandas">Francisco Grandas</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital General Universitario “Gregorio Marañón”, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Nomoto, Masahiro" sort="Nomoto, Masahiro" uniqKey="Nomoto M" first="Masahiro" last="Nomoto">Masahiro Nomoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Therapeutic Medicine, Faculty of Medicine, Ehime University Hospital, Ehime</wicri:regionArea><wicri:noRegion>Ehime</wicri:noRegion></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-30">2007-07-30</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1379">1379</biblScope><biblScope unit="page" to="1389">1389</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CC3323805F38A8257F0A40F3113E504989102B49</idno><idno type="DOI">10.1002/mds.21475</idno><idno type="ArticleID">MDS21475</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson</term><term>dyskinesia</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms also occur, making the evaluation and choice of treatment complicated. A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway. This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata. Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism. Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, α2 adrenergic, serotonergic (5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid CB1 receptors systems. The only currently available drug with an evidence‐based recommendation on efficacy for dyskinesia is amantadine. Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically. New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>Espagne</li><li>Italie</li><li>Japon</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Illinois</li><li>Latium</li></region><settlement><li>Madrid</li><li>Rome</li></settlement></list><tree><country name="Italie"><region name="Latium"><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name></region></country><country name="Canada"><noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Grandas, Francisco" sort="Grandas, Francisco" uniqKey="Grandas F" first="Francisco" last="Grandas">Francisco Grandas</name></region></country><country name="Japon"><noRegion><name sortKey="Nomoto, Masahiro" sort="Nomoto, Masahiro" uniqKey="Nomoto M" first="Masahiro" last="Nomoto">Masahiro Nomoto</name></noRegion></country><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001027 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001027 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CC3323805F38A8257F0A40F3113E504989102B49
|texte= Levodopa‐induced dyskinesias
}}
| This area was generated with Dilib version V0.6.23. |  |